title: [The effect of benzbromarone on hyperlipidemia in gout].
abstract: It is well known that triglycerides and cholesterol are often increased in gout. In 50% of the patients with hyperuricemia and in 40% of the patients with gout hyperlipidemia is found. K. Kŭnev has found in his former studies that the treatment with the drug Desuric leads to a decrease of cholesterol and other lipids in the blood. The follow up of 38 men with proved gout, mean age 45 years and mean duration of the disease 5 years, established an increase mainly of endogenous triglycerides and cholesterol. Benzbromarone treatment, 50-100 mg daily, led to a parallel decrease of serum lipids and uric acid. This allows benzbromarone to be recommended for the treatment of hyperlipidemia in gout which will lead to a decrease of the vascular complications and mortality in gout.
authors.forename: L
authors.initials: L
authors.lastname: Marinchev
authors.forename: K
authors.initials: K
authors.lastname: Kŭnev
mesh_terms: D000328:Adult; D001553:Benzbromarone / Q000627:therapeutic use*; D004341:Drug Evaluation; D006073:Gout / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000960:Hypolipidemic Agents; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids; D001553:Benzbromarone
vernacular_title: Vliianie na benzbromarona vŭrkhu khiperlipidemiiata pri podagra.